Coffin James 4

4 · Sema4 Holdings Corp. · Filed Jul 26, 2021

Form 4

Period: 2021-07-22

President and COO

Transactions

Award
Employee Stock Option (Right to Buy)
2021-07-22+480,657→ 480,657 total
Exercise: $0.77Exp: 2030-02-17→ Class A Common Stock (480,657 underlying)
Award
Employee Stock Option (Right to Buy)
2021-07-22+332,963→ 332,963 total
Exercise: $0.77Exp: 2030-02-17→ Class A Common Stock (332,963 underlying)
Award
Employee Stock Option (Right to Buy)
2021-07-22+2,167,093→ 2,167,093 total
Exercise: $0.15Exp: 2027-08-30→ Class A Common Stock (2,167,093 underlying)

Footnotes (2)

[F1]6.25% of the total shares underlying the option vest in quarterly installments until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
[F2]Pursuant to the business combination between the Issuer (which was formerly known as CM Life Sciences, Inc.) and Mount Sinai Genomics, Inc. d/b/a Sema4 ("Sema4"), each share of Sema4 outstanding common stock was automatically converted into the right to shares of the Issuer's Class A Common Stock based on a 1 to 123.8338 exchange ratio ("Exchange Ratio"). In addition, each outstanding Sema4 equity award was automatically converted into a corresponding equity award of the Issuer based on the Exchange Ratio and with the same terms and vesting conditions as the Sema4 equity awards.

Documents

1 file